Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe The company recorded progress towards its sustainability targets Sustainability is one of the essential drivers for future BAD HOMBURG, Germany , Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices.

Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

BAD HOMBURG, Germany , Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of the German Stock Index, the DAX 40, as of December 27, 2024. The index represents the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange and accounts for around 80 percent of the market capitalization of listed stock corporations in Germany.

Fresenius Medical Care returns to Dax 40 Index

Deluxe

General Motors

Tyson Foods

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. TSN, GM, FMS and DLX boast a low P/CF ratio.

4 Value Stocks to Buy as Wall Street Awaits Fed's Rate Decision

City Office REIT

TPG RE Finance Trust

ZIM Integrated Shipping Services

The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, FMS, CIO, TRTX and ZIM are some such stocks.

5 Low Price-to-Book Value Stocks to Buy as 2024 Draws to a Close

Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.

Leadership in Dialysis Services and Products Drives FMS Stock

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Fresenius (FMS) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?

FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.

Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?

Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Oliver Metzger - ODDO BHF Bank Sezgi Oezener - HSBC Giang Nguyen - Citigroup David Adlington - JPMorgan Marianne Bulot - Bank of America Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the report of the Third Quarter 2024 of Fresenius Medical Care Conference Call. I'm Sandra, the Chorus Call operator.

Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript

Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous range BAD HOMBURG, Germany , Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year.

Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024

Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?

A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024

Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.

Fresenius Medical Care: Let's Look At The Upside

Here's Why Fresenius (FMS) is a Strong Momentum Stock

Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.

Reasons to Retain Fresenius Medical Stock in Your Portfolio Now

Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term

FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.

Fresenius Medical Care Stock Rises on NxStage VersiHD Launch

Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience WALTHAM, Mass. , Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers.

Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company?

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up

Fresenius Medical Care AG (NYSE:FMS ) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Richard Felton - Goldman Sachs Graham Doyle - UBS Hassan Al-Wakeel - Barclays Victoria Lambert - Berenberg Hugo Solvet - BNP Paribas James Vane-Tempest - Jefferies David Adlington - JPMorgan Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Marianne Bulot - Bank of America Dominik Heger Thank you, Alice. Good morning, good afternoon or good evening, depending on where you are.

Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target range Further divestitures closed as execution of portfolio optimization program continues Net financial debt and net leverage ratio further improved FY 2024 outlook confirmed BAD HOMBURG, Germany , July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG.

Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024

News for Fresenius Medical Care Stock (FMS)